Demographic characteristics, admission investigations and outcomes of patients for those admitted for possible COVID-19
| Patient demographics | All admitted patients | Patients completing EIH assessment | ||||
| COVID-19 infection | No COVID-19 infection | |||||
| n=127 | n=26 | n=72 | ||||
| n (%) | 95% CI (SD) (IQR) | n (%) | 95% CI (SD) (IQR) | n (%) | 95% CI (SD) (IQR) | |
| Age (years) | 57.8 | (±16.3) | 51.6 | (±13.0) | 55.1 | (±15.6) |
| Male | 52 (40.9%) | 32.3% to 50.0% | 12 (46.2%) | 26.6% to 66.6% | 27 (37.5%) | 26.4% to 49.7% |
| Female | 75 (59.1%) | 50.0% to 67.7% | 14 (53.8%) | 33.4% to 73.4% | 45 (62.5%) | 50.3% to 73.6% |
| Respiratory medical history | ||||||
| None | 107 (84.3 %) | 76.7% to 90.1% | 25 (96.2%) | 80.3% to 99.9% | 61 (84.7 %) | 74.3% to 92.1% |
| Chronic Obstructive Pulmonary Disease | 14 (11.0 %) | 6.2% to 17.8% | 0 (0%) | – | 7 (9.7 %) | 4.0% to 19.0% |
| Pulmonary fibrosis | 4 (3.2 %) | 0.9% to 7.9% | 1 (3.8%) | 0.1% to 19.6% | 2 (2.8 %) | 0.3% to 9.7% |
| Chronic Pulmonary Thromboembolism | 2 (1.6 %) | 0.2% to 5.6% | 0 (0%) | 2 (2.8 %) | 0.3% to 9.7% | |
| Admission investigations | ||||||
| EIH >3% | 27 (27.6 %) | 18.3% to 37.1% | 11 (42.3 %) | 23.4% to 63.1% | 16 (22.2 %) | 13.2% to 33.6% |
| Median CRP (mg/L) | 16 | (6–65) | 65 | (34–139) | 6 | (6–22) |
| CRP >100 mg/L | 22 (18.2 %) | 11.8% to 26.2% | 9 (39.1%) | 19.7% to 61.4% | 5 (7.1%) | 2.4% to 15.9% |
| Median lymphocyte count (×109/L) | 1.5 | (0.9–2.2) | 1.3 | (0.9–1.9) | 1.9 | (1.2–2.5) |
| Lymphocyte <1.0×109/L | 35 (28.0%) | 20.3% to 36.7% | 8 (32.0%) | 14.5% to 53.5% | 12 (16.9%) | 9.0% to 27.7% |
| CXR findings | ||||||
| Suggestive of COVID-19 | 20 (16.3%) | 3.3% to 24.0% | 14 (56.0%) | 34.9% to 75.6% | 1 (1.4%) | 0.4% to 7.8% |
| Indeterminate | 14 (11.4%) | 6.4% to 18.4% | 4 (16.0%) | 4.5% to 36.1% | 5 (7.2%) | 2.4% to 16.1% |
| Not suggestive of COVID-19 | 89 (72.4%) | 63.6% to 80.0% | 7 (28.0%) | 12.1% to 49.4% | 63 (91.3%) | 82.0% to 96.7% |
| Length of symptoms (days) | 6 | (2–14) | 8.5 | (4–14) | 6 | (3–14) |
| Self-reported dyspnoea | 89 (70.1%) | 61.3% to 77.9% | 23 (88.5%) | 69.8% to 97.6% | 45 (62.5%) | 50.3% to 73.6% |
| Patient outcomes | ||||||
| Supplemental oxygen | 29 (22.8%) | 15.9% to 31.1% | 11 (42.3%) | 23.4% to 63.1% | 6 (8.3%) | 3.1% to 17.3% |
| Median length of stay (days) | 4 | (2–6) | 4 | (3–6) | 3 | (2–6) |
CRP, C-reactive protein; EIH, exercise-induced hypoxia.